Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial.

Left ventricular (LV) dysfunction c-kit-positive, lineage-negative cardiac stem cells (CSC) improving post-infarction when given to animals. We conducted an experiment phase 1 (Stem Cell Infusion in Patients with ischemic cardiomyopathy [Scipio]) from autologous CSC for the treatment of heart failure due to ischemic heart disease.In trial stage A Scipio, patients with post-infarction LV dysfunction (ejection fraction [EF] ≤ 40%) prior to coronary artery bypass grafting were consecutively enrolled in the treatment and control groups. In stage B, patients were randomly assigned to treatment or control groups in a ratio of 2: 3 by using the block scheme of computer-generated randomization. 1 million autologous CSC given by intracoronary infusion at an average of 113 days (SE 4) after surgery; untreated controls.

Although this study is an open label, echocardiographic analysis did not know the duties of the group. The primary endpoint was a short-term security of CSC and the secondary endpoint was efficacy. A per-protocol analysis were used. This study is registered with ClinicalTrials.gov, number NCT00474461.This study is still in progress. 16 patients were assigned to the treatment group and seven for the control group; no side effects were reported related CSC.

On 14 CSC-treated patients were analyzed, LVEF increased from 30 · 3% (SE 1 · 9) before CSC infusion to 38 · 5% (2 · 8) at 4 months after infusion (p = 0 · 001). In contrast, the seven control patients, as long as the appropriate time interval, LVEF did not change (30 · 1% [2 · 4] at 4 months after CABG vs 30 · 2% [2 · 5] at 8 months after CABG). Importantly, CSC healthful effects are even more pronounced in the first year in eight patients (eg, LVEF increased by 12 · 3 unit ejection fraction [2 · 1] vs baseline, p = 0 · 0007).

In seven patients treated in whom cardiac MRI can be done, infarct size decreased from 32 · 6 g (6 · 3) by 7 · 8 g (1 · 7; 24%) at 4 months (p = 0 · 004) and 9 · 8 g (3 · 5; 30%) at 1 year (p = 0 · 04) .This preliminary results in patients with very encouraging. They suggest that intracoronary infusion of autologous CSC effective in improving LV systolic function and reduced infarct size in patients with heart failure after myocardial infarction, and warrant further, larger, phase 2 studies.University of Louisville Research Foundation and the National Institutes of Health ,

D-Luciferin sodium salt
B8311-10 10 mg
EUR 131

D-Luciferin sodium salt
B8311-200 200 mg
EUR 699

D-Luciferin sodium salt
B8311-50 50 mg
EUR 293

D-Luciferin, Sodium Salt
7902-100
EUR 120

D-Luciferin, Sodium Salt
7902-10G
EUR 2409

D-Luciferin, Sodium Salt
7902-10PK
EUR 2763

D-Luciferin, Sodium Salt
7902-1G
EUR 354

D-Luciferin, Sodium Salt
7902-25G Ask for price

D-Luciferin, Sodium Salt
7902-3PK
EUR 925

D-Luciferin, Sodium Salt
7902-50G Ask for price

D-Luciferin, Sodium Salt
7902-5PK
EUR 1496

D-Luciferin potassium salt
HY-12591B 50mg
EUR 153

D-Luciferin, Potassium Salt
D0510-010 100mg
EUR 185

D-Luciferin, Potassium Salt
D0510-050 500mg
EUR 504

D-Luciferin, Potassium Salt
D0510-100 1g
EUR 847

D-Luciferin, potassium salt
10101 10MG
EUR 112
Description: Minimum order quantity: 1 unit of 10MG

D-Luciferin, potassium salt
10101-1 50MG
EUR 234
Description: Minimum order quantity: 1 unit of 50MG

D-Luciferin, potassium salt
10101-2 1G
EUR 714
Description: Minimum order quantity: 1 unit of 1G

D-Luciferin, Potassium Salt
7903-100
EUR 120

D-Luciferin, Potassium Salt
7903-10G
EUR 2409

D-Luciferin, Potassium Salt
7903-10PK
EUR 2763

D-Luciferin, Potassium Salt
7903-1G
EUR 354

D-Luciferin, Potassium Salt
7903-25G Ask for price

D-Luciferin, Potassium Salt
7903-3PK
EUR 925

D-Luciferin, Potassium Salt
7903-50G Ask for price

D-Luciferin, Potassium Salt
7903-5PK
EUR 1496

D-Luciferin, sodium salt *CAS#: 103404-75-7*
12509 25 mg
EUR 115

D-Luciferin, sodium salt *CAS#: 103404-75-7*
12510 100 mg
EUR 132

D-Luciferin, sodium salt *CAS#: 103404-75-7*
12511 1 g
EUR 528

EZSolution? D-Luciferin, Potassium Salt
B3001-set
EUR 370

Brite-Light? D-Luciferin, Potassium Salt
B3000-10PK
EUR 2268

Brite-Light? D-Luciferin, Potassium Salt
B3000-1G
EUR 327

Brite-Light? D-Luciferin, Potassium Salt
B3000-5PK
EUR 1300

D-Luciferin
HY-12591A 10mg
EUR 108

D-Luciferin
GP9319-100MG 100 mg
EUR 221

D-Luciferin
GP9319-10MG 10 mg
EUR 70

D-Luciferin
GP9319-25MG 25 mg
EUR 110

D-Luciferin
GP9319-50MG 50 mg
EUR 150

D-Luciferin
B6040-10 10 mg
EUR 131
Description: D-luciferin is a cell-permeable chemiluminescent luciferase substrate with a Km of approximately 2 ?M. D-luciferin could emit lights upon oxidative decarboxylation in the presence of ATP.

D-Luciferin
B6040-200 200 mg
EUR 699
Description: D-luciferin is a cell-permeable chemiluminescent luciferase substrate with a Km of approximately 2 ?M. D-luciferin could emit lights upon oxidative decarboxylation in the presence of ATP.

D-Luciferin
B6040-50 50 mg
EUR 293
Description: D-luciferin is a cell-permeable chemiluminescent luciferase substrate with a Km of approximately 2 ?M. D-luciferin could emit lights upon oxidative decarboxylation in the presence of ATP.

D-Luciferin, potassium salt *CAS#: 115144-35-9*
12505 25 mg
EUR 115

D-Luciferin, potassium salt *CAS#: 115144-35-9*
12506 100 mg
EUR 132

D-Luciferin, potassium salt *CAS#: 115144-35-9*
12507 1 g
EUR 263

D-Luciferin acetate
12516 5 mg
EUR 219

D-Glucuronic acid, sodium salt, monohydrate
GB0483 5g
EUR 107.42

Methyl beta-D-glucuronide sodium salt
GC4190-1G 1 g
EUR 229

Methyl beta-D-glucuronide sodium salt
GC4190-250MG 250 mg
EUR 110

D-Glucuronic acid sodium salt monohydrate
GC8431-100G 100 g
EUR 126

D-Glucuronic acid sodium salt monohydrate
GC8431-250G 250 g
EUR 229

D-Glucuronic acid sodium salt monohydrate
GC8431-25G 25 g
EUR 70

D-Glucuronic acid sodium salt monohydrate
GC8431-5G 5 g
EUR 46

D-Glucosamine 2-sulfate sodium salt
GC9126-25MG 25 mg
EUR 61

Estradiol 17-(?-D-Glucuronide) (sodium salt)
C3840-5 5 mg
EUR 132
Description: Km: 75 ?MEstradiol 17-(?-D-Glucuronide) is a substrate of the multidrug resistance protein 2 (MRP2).MRP2 is a member of the superfamily of ATP-binding cassette (ABC) transporters, which transport various molecules across extra- and intra-cellular membranes.

Estradiol 17-(?-D-Glucuronide) (sodium salt)
C3840-10 10 mg
EUR 206
Description: Km: 75 ?MEstradiol 17-(?-D-Glucuronide) is a substrate of the multidrug resistance protein 2 (MRP2).MRP2 is a member of the superfamily of ATP-binding cassette (ABC) transporters, which transport various molecules across extra- and intra-cellular membranes.

Estradiol 17-(?-D-Glucuronide) (sodium salt)
C3840-25 25 mg
EUR 338
Description: Km: 75 ?MEstradiol 17-(?-D-Glucuronide) is a substrate of the multidrug resistance protein 2 (MRP2).MRP2 is a member of the superfamily of ATP-binding cassette (ABC) transporters, which transport various molecules across extra- and intra-cellular membranes.

Estradiol 17-(?-D-Glucuronide) (sodium salt)
C3840-50 50 mg
EUR 502
Description: Km: 75 ?MEstradiol 17-(?-D-Glucuronide) is a substrate of the multidrug resistance protein 2 (MRP2).MRP2 is a member of the superfamily of ATP-binding cassette (ABC) transporters, which transport various molecules across extra- and intra-cellular membranes.

Estradiol 3-(?-D-Glucuronide) (sodium salt)
C3897-1 1 mg
EUR 118
Description: ?-estradiol 3-(?-d-glucuronide) (E23G) is a noncholestatic regioisomer of the estrogen metabolite, E217G (?-Estradiol 17-(?-d-glucuronide)) [1]. E23G functions as a substrate for multidrug resistance associated protein 2 (MRP2) [2].

Estradiol 3-(?-D-Glucuronide) (sodium salt)
C3897-10 10 mg
EUR 527
Description: ?-estradiol 3-(?-d-glucuronide) (E23G) is a noncholestatic regioisomer of the estrogen metabolite, E217G (?-Estradiol 17-(?-d-glucuronide)) [1]. E23G functions as a substrate for multidrug resistance associated protein 2 (MRP2) [2].

Estradiol 3-(?-D-Glucuronide) (sodium salt)
C3897-25 25 mg
EUR 1073
Description: ?-estradiol 3-(?-d-glucuronide) (E23G) is a noncholestatic regioisomer of the estrogen metabolite, E217G (?-Estradiol 17-(?-d-glucuronide)) [1]. E23G functions as a substrate for multidrug resistance associated protein 2 (MRP2) [2].

Estradiol 3-(?-D-Glucuronide) (sodium salt)
C3897-5 5 mg
EUR 306
Description: ?-estradiol 3-(?-d-glucuronide) (E23G) is a noncholestatic regioisomer of the estrogen metabolite, E217G (?-Estradiol 17-(?-d-glucuronide)) [1]. E23G functions as a substrate for multidrug resistance associated protein 2 (MRP2) [2].

D-Luciferin, free acid
10100 10MG
EUR 112
Description: Minimum order quantity: 1 unit of 10MG

D-Luciferin, free acid
10100-1 50MG
EUR 234
Description: Minimum order quantity: 1 unit of 50MG

D-Luciferin, free acid
10100-2 1G
EUR 714
Description: Minimum order quantity: 1 unit of 1G

D-Luciferin (Free acid)
2779-1000
EUR 338

D-Luciferin (Free acid)
2779-250
EUR 175

D-Luciferin (Free acid)
2779-500
EUR 251

D-Luciferin (Free acid)
2779-5000
EUR 1273

Cromolyn sodium salt
SB0843 5g
EUR 65.66

Methotrexate sodium salt
M031-250MG 250 mg
EUR 117

Monensin Sodium Salt
M083-1G 1 g
EUR 71

Monensin Sodium Salt
M083-5x1G 5 x 1 g
EUR 159

MES, sodium salt
MB0611 50g
EUR 74.36

MOPSO, sodium salt
MDB0095 25g
EUR 63.92

MOPS, sodium salt
MDB360S 100g
EUR 89.15

Entacapone (sodium salt)
HY-14280A 10mg
EUR 119

Grazoprevir sodium salt
HY-15298C 10mg
EUR 243

Luminol (sodium salt)
HY-15922A 500mg
EUR 108

Salinomycin (sodium salt)
HY-17439 100mg
EUR 187

Heparin (sodium salt)
HY-17567A 500mg
EUR 147

Seladelpar sodium salt
HY-19522A 10mM/1mL
EUR 163

Etomoxir (sodium salt)
HY-50202A 5mg
EUR 147

Silmitasertib (sodium salt)
HY-50855B 10mg
EUR 187

Cefotaxime (sodium salt)
HY-A0088 10mM/1mL
EUR 113

Adapalene (sodium salt)
HY-B0091A 500mg
EUR 326

Cefoperazone (sodium salt)
HY-B0210A 500mg
EUR 108

Sulfamerazine (sodium salt)
HY-B0512A 500mg
EUR 131

Azlocillin (sodium salt)
HY-B0529A 500mg
EUR 113

Ceftriaxone (sodium salt)
HY-B0712B 500mg
EUR 173

Citicoline sodium salt
HY-B0739A 100mg
EUR 108

Bucladesine (sodium salt)
HY-B0764 50mg
EUR 139

Cloprostenol sodium salt
HY-108415 10mg
EUR 349

Fosmidomycin sodium salt
HY-112853 5mg
EUR 349

Zidebactam sodium salt
HY-120859A 10mg
EUR 1025

Resorufin sodium salt
HY-123533A 100mg
EUR 142

Batimastat (sodium salt)
HY-13564A 5mg
EUR 187
Scroll to Top